Type 1 Diabetes Technology and Devices

Closed Loop from Onset in type 1 Diabetes (CLOuD)

Investigator:

Roman Hovorka, rh347@cam.ac.uk

Summary:

CLOuD is a multicentre, randomised trial of an exciting new artificial pancreas device, in newly diagnosed adolescents with type 1 diabetes (T1D). It is designed to mimic the normal activity of beta-islet pancreatic cells in response to blood glucose levels. The device is a closed loop system combining real-time continuous glucose monitoring with insulin pump therapy and a computer-based algorithm to calculate the amount of insulin required to keep blood glucose levels within target range. The aim is to prolong residual insulin secretion after T1D diagnosis, via intensive metabolic control using the artificial pancreas closed loop system, in order to minimise long-term complications and reduce the risk of hypoglycaemia. 96 newly diagnosed subjects with T1D will be randomised 1:1 to either closed loop or standard therapy (multiple daily injections). Participants will have study visits and assessments every 3 months for a total of 24 months.
Start Date: January 2017
End Date: October 2021

Further Information:

CLOuD website: http://cloud.mrl.ims.cam.ac.uk/

ClinicalTrials.gov (NCT02871089): https://clinicaltrials.gov/ct2/show/NCT02871089?cond=Diabetes+Mellitus%2C+Type+1&cntry=GB&city=Cambridge&draw=2&rank=19

 

KidsAp01

Investigator:

Roman Hovorka rh347@cam.ac.uk

Summary:

The suggested clinical trial is part of the KidsAP project funded by the European Commission's Horizon 2020 Framework Programme. The project evaluates the use of the Artificial Pancreas (or closed loop systems) in very young children with type 1 diabetes (T1D) aged 1 to 7 years. The suggested trial is a feasibility study to pilot the setup of a large-scale outcome trial and to address the specific needs of this population. The results of the pilot trial will feed into the design of the outcome study.

In this study the investigators will compare closed loop insulin delivery using standard strength insulin to closed loop use with diluted insulin in very young children with T1D. Diluted insulin is a standard treatment approach for children with low insulin requirements.

Start Date: August 2017
End Date: April 2018

Further Information:

http://kidsap.mrl.ims.cam.ac.uk/

 

Day and Night Closed-loop in Young People With Type 1 Diabetes (DAN05)

Investigator:

Roman Hovorka rh347@cam.ac.uk

Summary:

The main study objective is to determine whether 24/7 automated closed-loop glucose control combined with low glucose feature will improve glucose control as measured by HbA1c.

This is an open-label, multi-centre, multi-national, single-period, randomised, parallel group design study, involving a 6 month period of home study during which day and night glucose levels will be controlled either by a closed-loop system combined with low glucose feature (intervention group) or by insulin pump therapy alone (control group).

Start Date: January 2018
End Date: October 2018

Further Information:

 

 

Paediatric Use of the Abbott Sensor Based Glucose Monitoring System for 21 days – an Accuracy Evaluation (PUGs)

Investigator:

Joe Bugler joe.buglar@abbott.com

Summary:

Accuracy evaluation of the Abbott Sensor Based Glucose Monitoring System when used by children with diabetes. This is a single arm study, using the Abbott Sensor Based Glucose Monitoring System for up to 21 days. Participants will wear a masked (blinded) Sensor for a period of up to 21 days. Participants will be asked to scan the Sensor with the Reader immediately after obtaining a fingerprick reading.

Start Date: February 2018

End Date: April 2018

Further Information:

www.diabetescare.abbott